Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: the open-label Study 342 (FREEDOM Study) (vol 5, pg 274, 2020)

被引：0

|

作者：

Yamamoto

机构：

来源：

EPILEPSIA OPEN | 2020年 / 5卷 / 03期

关键词：

D O I：

10.1002/epi4.12416

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：518 / 518

页数：1

相关论文

共 43 条

[41] A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations (vol 99, e23455, 2020)
Song, S-Y
Ha, S-J
Park, J-H
MEDICINE, 2022, 101 (02)
[42] A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy
Jamy, Omer Hassan
Khan, Sharif S.
Tsirigotis, Panagiotis
Tomlinson, Benjamin Kent
Hunault-Berger, Mathilde
Platzbecker, Uwe
Sakellari, Ioanna
Vidovic, Ana
Montesinos, Pau
del Castillo, Teresa Bernal
Egan, Daniel
Safah, Hana
Schiller, Gary J.
Haenel, Mathias
Obara, Agata
Chen, Tsung-Chih
Rotta, Marcello
Giannouli, Stavroula
Savic, Aleksandar
Cicic, Dragan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥18 y with newly diagnosed (ND) FLT3-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).
Fuentes, Adolfo
Ben Ali, Moez
Maier, Joan
Deniau, Ythier
Ruault, Anne
Cuenot, Laura
Campello-Iddison, Valerie
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →